Unlock the Potential of HeLa Cells for Innovative Screening Solutions

CD BioGlyco utilizes the versatility of HeLa cells to provide in vitro screening services. We provide a platform for In Vitro Glycobiology Disease Model Screening Service to help clients screen potential carbohydrates and investigate glycosylation disease mechanisms. Furthermore, In Vivo Glycobiology Disease Model Screening Service is also provided to enable clients to validate findings from in vitro studies in more complex biological systems. Our services are comprehensive to guarantee that clients find whatever research they need.

HeLa cells have long been celebrated for their robustness and versatility in scientific research and medical applications. Despite originating as cancer cells, they exhibit fundamental characteristics similar to those of healthy cells, such as gene expression, protein synthesis, and metabolic regulation. By providing HeLa cells-based in vitro screening service, CD BioGlyco will help clients to facilitate and advance research endeavors in the field of drug development and research. Our service is significant in exploring human biology, modeling diseases, and researching intricate molecular mechanisms underlying cellular functions.

Fig.1 Scanning electron micrograph of an apoptotic HeLa cell. (Wikipedia, 2013)

Our Services

We utilize this cell line because it possesses the following characteristics:

• HeLa cells proliferate swiftly and are easily maintained in culture
• HeLa cells are notably prone to infections by various viruses.
• HeLa cells serve as excellent hosts for transfection studies.

• Anti-cancer carbohydrate screening: We employ HeLa cells to screen for carbohydrates or related compounds that exhibit inhibitory activity against cancer cell proliferation. Through this screening process, we aim to identify lead compounds with a significant anti-cancer potential.
  • In order to guarantee the reliability of experiments, we have developed protocols for growing and harvesting HeLa cells in a manner that allows them to be manipulated easily and adapted to different cultures.
  • We will perform the MTT assay to screen the cytotoxicity of carbohydrate-related compounds against HeLa cells. HeLa cell lines are plated in 96-well plates with varying concentrations of compounds. The viability will be measured by the MTT assay and IC₅₀ values will be determined.
  • Subsequently, HeLa cells will be treated with carbohydrate-related compounds of interest for specified durations, fixed with ethanol, stained with propidium iodide (PI), and analyzed using flow cytometry to determine cell cycle distribution.
  • Finally, normal cells are treated with compounds, stained with Annexin V-FITC and PI, and analyzed by using flow cytometry to assess apoptosis rates.

Through these comprehensive assays, we evaluate the cytotoxic effects, cell viability, cell cycle alterations, and induction of apoptosis by test compounds, providing crucial insights into their potential as anti-cancer agents.

Drug discovery for other diseases: Additionally, we utilize HeLa cells to facilitate the screening of carbohydrate-related compounds against a spectrum of diseases beyond cancer. By infecting HeLa cells with different bacteria or pathogens, we can screen for potential drug candidates targeting various illnesses. Two experimental schemes will be conducted for the collection of HeLa cell supernatants to determine cytokine levels.

• Firstly, we use the pre-treatment model where HeLa cells are initially exposed to those target compounds. Subsequently, these pre-treated HeLa cells will be challenged with bacteria or pathogens for several hours. In this design, we aim to replicate a scenario where treatment occurs before the onset of the disease, thus simulating preventive research.
• Secondly, we construct the post-treatment model. HeLa cells will be first challenged with the bacteria or pathogens for several hours. Following this challenge, the cells will be treated with target carbohydrates for several hours under the same incubation conditions. This experiment simulates the disease onset initially, followed by the administration of treatment, representing curative research.

Through our two distinct experimental protocols, we will help clients research the realms of disease prevention as well as treatment, thereby broadening our understanding of both prophylactic measures and therapeutic interventions.

Publication Data

Advantages

• Our HeLa cells-based in vitro screening service harnesses the potential of HeLa cells to deliver innovative solutions in drug discovery, toxicity assessment, and biological research.
• With a focus on efficiency, reliability, and scientific rigor, our service caters to the diverse needs of researchers and pharmaceutical companies alike.
• Our service process begins with meticulous cell culture techniques to ensure the optimal growth and viability of HeLa cells.
• Whether you require high-throughput screening for drug discovery or detailed toxicity testing, our assays are designed to deliver accurate and reproducible results.

Frequently Asked Questions

• What does the HeLa cell structure entail?

The HeLa cells exhibit a structure akin to typical human cells, comprising a cell membrane, cytoplasm, various organelles, and a nucleus. Nevertheless, due to their extensive mutations, HeLa cells often possess multiple nuclei, which deviates from the norm.

• What kind of studies are conducted using HeLa cells?

HeLa cells have been pivotal in diverse research fields, from understanding radiation and toxins' effects to developing cancer treatments and vaccines. They have played a crucial role in many disease research, such as:

Beyond medicine, HeLa cells aid in studying cell division, communication, responses to stimuli, aging, and cancer development.

At CD BioGlyco, we offer a comprehensive solution for screening carbohydrate-based drug candidates and assessing compound toxicity. Our service provides clients with efficient and reliable research tools to aid in disease model development and biological studies. Leveraging the robustness and versatility of HeLa cells, this service offers a platform for screening potential therapeutic carbohydrates, investigating disease mechanisms, and exploring various aspects of glycobiology. Through our Glycobiology Disease Model Development Service, we provide tailored solutions for the establishment and characterization of disease models related to glycosylation disorders and other glycobiology-related conditions. Our comprehensive approach encompasses assay development, compound screening, data analysis, and interpretation, enabling clients to gain valuable insights into disease pathogenesis and identify novel therapeutic targets. If you're interested in our services, please feel free to contact us. We're here to assist you with any inquiries or to provide further information about how our offerings can support your research and development efforts.